|
|
|
|
 Dr Margaret Beer,
Senior Director and Head of Licensing and External Research Merck & Co Margaret Beer studied at the Universities of Reading and London before carrying out her research work on serotonin pharmacology. She joined Merck, as a bench neuroscientist, in 1984 following her return to the UK from Stanford University.
She is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis.
Margaret joined Merck's Worldwide Licensing and External Research, Europe, group in 2003. This group was established in 2002 specifically in recognition of the scientific excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008.
She is the co-author of 100 original research articles, review articles, and abstracts, and has presented widely at international professional meetings.Appearing: DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY 11.40am Opportunities offered by Merck’s scientifically-driven licensing models in oncology
- Opportunity for biotech: what kind of opportunities is the company looking to bring in?
- Understanding the broad assortment of deal-types available with examples.
- Opportunity for Big Pharma: what can be learned from Merck’s intelligent approach to partnerships and licensing in the oncology space?
Dr Margaret Beer, Senior Director and Head of Licensing and External Research,
Merck & Co |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
